Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals — Investor Presentation (January 2024)

26 slides from Fusion Pharmaceuticals's investor presentation, Jan 4, 2024

  1. Slide 1: Corporate Presentation January 2024

    Corporate Presentation January 2024 Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements that are based on our management's belief and assumptions and on information currently avai

  3. Slide 3: Fusion is a Leader in the Radiopharmaceutical Space

    Fusion is a Leader in the Radiopharmaceutical Space Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved 3 Positioned to be first Ac-PSMA targeted radiotherapy to market for treatment of post-lutetium mCRPC, if approved; achieved alignment with FDA on potential registration pathway Lead

  4. Slide 4: Lead Program: FPI-2265

    Lead Program: FPI-2265 Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved

  5. Slide 5: FPI-2265 is Currently the Most Advanced Actinium-Based PSMA Targeted Radiotherapy in Development

    FPI-2265 is Currently the Most Advanced Actinium-Based PSMA Targeted Radiotherapy in Development More than 300 patients treated with 225Ac-PSMA globally, including ~100 post-177Lu-PSMA Achieved clinical POC in mCRPC Safety results supportive of developability (manageable hematological toxicity and x

  6. Slide 6: Target Enrollment Complete in TATCIST Study: Data Readout Anticipated in April 2024

    Target Enrollment Complete in TATCIST Study: Data Readout Anticipated in April 2024 Generally consistent with previously published data PSA50 response: ~30-50% Mix of patients who are pre- and post-lutetium, with majority naïve to Pluvicto Safety profile mostly limited to manageable xerostomia (Grad

  7. Slide 7: Fusion Aligns with FDA on Potential Registrational Pathway

    Fusion Aligns with FDA on Potential Registrational Pathway Phase 2/3 Study Initiation Expected in Q2 2024 Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved 2:1 50kBq/kg every 4 weeks 75kBq/kg every 6 weeks 100kBq/kg every 8 weeks FPl-2265 Recommended Regimen ARAT Switch 1:1:1 Randomiz

  8. Slide 8: Potential FPI-2265 Market Opportunity in PLUVICTO Patients

    Potential FPI-2265 market opportunity: Significant and Rapidly Growing Market in PLUVICTO™ Patients Expands Potential FPI-2265 Opportunity Source: VISION results per clinicaltrials.gov (NCT03511664); 177Lu-PSMA-617 radiographic ORR = 29.8%, mDOR = 9.8 mo.; PSA50 = 46%; duration of PSA response = 8.9

  9. Slide 9: FPI-2265 Program Milestones

    FPI-2265 Program Milestones Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Milestone Timing Preliminary TATCIST Data from approximately 25-30 Patients April 2024 Initiate Phase 2/3 Registration Study Q2 2024 Initiate Combination Trial with Olaparib 1H 2024 Completion of Phase 2 Stu

  10. Slide 10: Actinium Supply & Manufacturing Capabilities

    Actinium Supply & Manufacturing Capabilities Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved

  11. Slide 11: Alpha-Emitting Radioisotopes Represent the Future of Radiopharma

    Alpha-Emitting Radioisotopes Represent the Future of Radiopharma Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Double vs single strand DNA breaks create greater physical damage to cancer cells In preclinical studies, shorter range and higher energy transfer rates resulted in more

  12. Slide 12: Fusion's Actinium Supply Designed to Provide Execution Advantage

    Fusion’s Actinium Supply Designed to Provide Execution Advantage Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Clinical Site Ac-225 Generator On demand Ra-225 Fusion’s multiple strategic actinium supply agreements provide Preferential access and pricing to actinium Ability to scal

  13. Slide 13: Fusion is Built on a Foundation of Radiopharmaceutical Manufacturing Expertise

    Fusion is Built on a Foundation of Radiopharmaceutical Manufacturing Expertise Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Internal GMP manufacturing is fully operational: FPI-2265 (225AcPSMA) doses being shipped Clinical & potential commercial supply capabilities Capacity desig

  14. Slide 14: Moving the Field Beyond Prostate and NETs: Fusion's Clinical-Stage Pipeline

    Moving the Field Beyond Prostate and NETs: Fusion’s Clinical-Stage Pipeline Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved

  15. Slide 15: Unlocking the Potential of Radiopharmaceuticals in Cancers Outside of Current Approved Indications

    Unlocking the Potential of Radiopharmaceuticals in Cancers Outside of the Few Current Approved Indications Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Discovery Preclinical/ IND Enabling Phase 1 Phase 2 Phase 3 FPI-2265* FPI-1434* FPI-2059 FPI-2068 Solid Tumors Expressing IGF-1R

  16. Slide 16: Fusion's Pipeline: Next Generation ADCs Using Lessons from PSMA

    Fusion’s Pipeline: Next Generation ADCs Using Lessons from PSMA PSMA SMDC vs. PSMA RLT in mCRPC Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Morris et al. (2017) J Clin Oncol 35, suppl; abstr 5038 PSA Best % change from Baseline EC1169 (PSMA-tubulysin) Pluvicto (177Lu-PSMA-617) H

  17. Slide 17: FPI-1434 Phase 1 Trial: A First-of-its-Kind Antibody-Based Targeted Alpha Therapy Study

    FPI-1434 Phase 1 Trial: A First-of-its-Kind Antibody-Based Targeted Alpha Therapy Study for Solid Tumors Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved “Cold” IGF-1R Antibody “Hot” IGF-1R antibody: FPI-1434 FPI-1434: An IGF-1R antibody carrying 225Ac: Delivering DNA damaging alpha

  18. Slide 18: Cohort in Cold+Hot Dosing Regimen Showed Promising Results that Supported Dose Escalation

    Cohort 1 in Cold+Hot Dosing Regimen Showed Promising Results that Supported Dose Escalation In June 2023, Fusion reported data from the first cold+hot dosing cohort at 15 kBq/kg: No DLTs, limited to transient Grade 1 or less thrombocytopenia 2/3 patients showed stable disease; ovarian patient receiv

  19. Slide 19: Encouraging Safety and Early Signals of Antitumor Activity at 25 kBq/kg

    Encouraging Safety and Early Signals of Antitumor Activity at 25 kBq/kg Safety: 2 out of 3 patients completed DLT period No DLTs, limited to transient Grade 1 or less thrombocytopenia (comparable to 15 kBq/kg) Activity: One patient (chordoma) showed stable disease; received 4 cycles of therapy One p

  20. Slide 20: Fusion's Early-Stage Pipeline

    Fusion’s Early-Stage Pipeline Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved

  21. Slide 21: Phase Ready Program: Next Generation ADCs with AstraZeneca Collaboration

    Phase 1 Ready Program Non-Small Cell Lung Cancer Model Recognizing the Potential of TATs as Next Generation ADCs with AstraZeneca Collaboration Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Fusion’s FastClear™ Linker EGFR binding cMET binding Ac-225 First Program Under Our Multi-A

  22. Slide 22: FPI-2059: A Small Molecule TAT Targeting Neurotensin Receptor 1 (NTSR1)

    FPI-2059: A small molecule TAT targeting Neurotensin Receptor 1 (NTSR1) Currently in Phase 1 dose escalation Fusion acquired the small molecule 177Lu radiopharmaceutical, IPN-1087, from Ipsen Human imaging data Promising early clinical safety data 225Ac-IPN-1087 Shows Single Dose Tumor Kill In Precl

  23. Slide 23: Fusion's Radiopharmaceutical & Oncology Drug Development Expertise

    Fusion’s Radiopharmaceutical & Oncology Drug Development Expertise Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved CHIEF OF STAFF Cara Ferreira, PhD PRESIDENT & CBO Mohit Rawat CLO Maria Stahl, JD CSO Chris Leamon, PhD CEO John Valliant, PhD CTO Eric Burak, PhD CFO John Crowley, CPA

  24. Slide 24: Unaudited Financials and 2024 Milestones

    Unaudited Financials and 2024 Milestones Unaudited Financials Extended Cash Runway ~$287M* Pro Forma Cash, Cash Equivalents and Investments Cash to Fund Operations extended into Q4 2025 Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved *Pro forma 9/30/23 cash, cash equivalents and inv

  25. Slide 25: Fusion is a Leader in the Radiopharmaceutical Space

    Fusion is a Leader in the Radiopharmaceutical Space Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved 25 Achieved alignment with FDA on potential registration pathway Lead Program AcPSMA in Phase 2/3 Actinium & Manufacturing Advantages Creating Next-Generation ADCs GMP radiopharma man

  26. Slide 26: Thank You

    www.FusionPharma.com Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Thank You

Fusion Pharmaceuticals — Investor Presentation (January 2024) on 6ix